Steroid therapy in clinically stable but serologically active systemic lupus erythematosus prevents severe disease flares

Expert Review of Clinical Immunology

Volumn 3, Issue 3, 2007, Pages 267-269

  Cardiel, Mario H ^a   Almagro, Raúl Menor ^b  

^a HOSPITAL GENERAL DR MIGUEL SILVA   (Mexico)

^b HOSPITAL DE JEREZ   (Spain)

Author keywords

Anti ds DNA antibodies; Randomized clinical trial; Severe disease flares; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; COMPLEMENT COMPONENT C3A; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPLEMENT BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPEPSIA; EARLY DIAGNOSIS; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; REMISSION; SCORING SYSTEM; SHORT COURSE THERAPY; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 34249680779     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.3.3.267     Document Type: Article

References (6)

1. Tseng CE, Buyon JP, Kim M et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 54, 3623-3632 (2006).
2. Arbuckle MR, McClain MT, Rubertone MV et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349, 1526-1533 (2003).
3. Gladman DD, Urowitz MB, Keystone EC. Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. Am. J. Med. 66, 210-215 (1979).
4. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus: I. General overview of biomarkers and their applicability. Arthritis Rheum. 50(6), 1709-1720 (2004).
5. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum. 50(7), 2048-2065 (2004).
6. Bootsma H, Spronk P, Derksen R et al. Prevention of relapse in systemic lupus erythematosus. Lancet 345, 1595-1599 (1995).